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ABSTRACT
The cdk inhibitor p57kip2, encoded by the Cdkn1c gene, plays a critical role in mammalian development and in
the differentiation of several tissues. Cdkn1c protein levels are carefully regulated via imprinting and other
epigenetic mechanisms affecting both the promoter and distant regulatory elements, which restrict its
expression to particular developmental phases or specific cell types. Inappropriate activation of these
regulatory mechanisms leads to Cdkn1c silencing, causing growth disorders and cancer. We have previously
reported that, in skeletal muscle cells, induction of Cdkn1c expression requires the binding of the bHLH
myogenic factor MyoD to a long-distance regulatory element within the imprinting control region KvDMR1.
Interestingly, MyoD binding to KvDMR1 is prevented in myogenic cell types refractory to the induction of
Cdkn1c. In the present work, we took advantage of this model system to investigate the epigenetic
determinants of the differential interaction of MyoD with KvDMR1. We show that treatment with the DNA
demethylating agent 5-azacytidine restores the binding of MyoD to KvDMR1 in cells unresponsive to Cdkn1c
induction. This, in turn, promotes the release of a repressive chromatin loop between KvDMR1 and Cdkn1c
promoter and, thus, the upregulation of the gene. Analysis of the chromatin status of Cdkn1c promoter and
KvDMR1 in unresponsive compared to responsive cell types showed that their differential responsiveness to
the MyoD-dependent induction of the gene does not involve just their methylation status but, rather, the
differential H3 lysine 9 dimethylation at KvDMR1. Finally, we report that the same histone modification also
marks the KvDMR1 region of human cancer cells in which Cdkn1c is silenced. On the basis of these results, we
suggest that the epigenetic status of KvDMR1 represents a critical determinant of the cell type-restricted
expression of Cdkn1c and, possibly, of its aberrant silencing in some pathological conditions.
Abbreviations: Cdkn1c, Cyclin-dependent kinase inhibitor 1C; CKI, Cyclin-dependent kinase inhibitor; KvDMR1, Kv-
differentially methylated region 1; CTCF, CCCTC-binding factor; BWS, Beckwith-Wiedemann syndrome; bHLH, basic-
helix-loop-helix; MeDIP, Methylated DNA immunoprecipitation; 5-AZA, 5-Azacytidine; H3K9me2, Histone H3 lysine 9
dimethylation; H3K9me3, Histone H3 lysine 9 trimethylation; ChIP, Chromatin immunoprecipitation; 3C, Chromo-
some conformation capture; DMEM, Dulbecco’s modified Eagle’s medium; FBS, Fetal bovine serum
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Introduction
p57kip2, encoded by the Cdkn1c gene, is a member of the Cip/
Kip family of cyclin-dependent-kinase inhibitors (CKIs) and
plays a key role in mammalian development by regulating cell
proliferation and differentiation in a number of different tis-
sues.1 Compared to the other Cip/Kip CKIs p21cip1 and p27kip1,
p57kip2 exerts unique functions not compensated by the other
family members, as suggested by the lethal phenotype of knock-
out mice2,3 and by the developmental anomalies associated with
Cdkn1c loss or misexpression in humans.4 The unique role of
the Cdkn1c protein has been ascribed both to the presence of
specific biochemical features of the protein, not shared by the
other family members,5,6 and to the specific expression pattern
of the gene.7 Cdkn1c is widely expressed in most tissues during
embryogenesis but its expression drastically decreases at birth,
becoming restricted to a subset of tissues and organs, such as
heart, brain, lung, kidney, pancreas, skeletal muscle, testis, and
placenta.8
The levels of Cdkn1c protein are fine-tuned by multiple
regulatory mechanisms, ranging from epigenetic to posttrans-
lational control, in different cell types.1 Moreover, Cdkn1c is a
paternally imprinted gene, expressed exclusively from the
maternal allele, in both human and mouse.9,10 Paternal
Cdkn1c is regulated by an imprinting control region, called
Kv-differentially methylated region 1 (KvDMR1), which con-
trols the imprinting of the Kcnq1 domain, a cluster of
imprinted genes including Cdkn1c.11 KvDMR1 is a 3.6 kb
sequence located about 150 kb at the 30 of Cdkn1c and bears
differential epigenetic marks on the 2 parental chromosomes,
such as DNA methylation and histone modifications.12-14 The
functional organization of KvDMR1 is highly conserved in
human and mouse. Two mechanisms of action have been
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proposed to explain the cis-acting repressive effect of this
imprinting control region. The first one would involve the
enhancer-blocking activity of paternal KvDMR1, mediated by
the insulator CCCTC-binding factor (CTCF).15 The second
one would involve chromatin silencing by paternally
expressed Kcnq1ot1, a macro noncoding RNA, the promoter
of which is comprised within the KvDMR1 CpG island,16 and
which has been suggested to regulate in cis the silencing of
adjacent genes by recruiting epigenetic modifiers.17 As found
for many imprinted genes, especially those involved in growth
control, alterations in the dosage of Cdkn1c expression cause
important functional consequences. In particular, Cdkn1c
defective expression is generally responsible for overgrowth
disorders, such as the Beckwith-Wiedemann syndrome
(BWS) and several cancer types, while Cdkn1c excessive
expression is associated with growth retardation disorders,
such as the Silver Russel syndrome.4,18
Although some information has been accumulated on the
regulatory strategies and molecular mechanisms involved in
the Cdkn1c silencing in cancer and in the paternal allele-spe-
cific repression during imprinting, much less is known about
the developmental regulation of this CKI, that is expected to
affect its maternal allele.
We have previously investigated the differentiation-depen-
dent regulation of Cdkn1c using the skeletal muscle system as a
model. We found that Cdkn1c is a target of the muscle-specific
basic helix-loop helix (bHLH) factor MyoD.19 MyoD is the pro-
totypical master regulator of differentiation20 and induces
Cdkn1c expression through a complex mechanism involving,
on one hand, the mediation of MyoD-induced factors, which
interact with Cdkn1c promoter21,22 and, on the other hand, the
direct interaction of MyoD with KvDMR1.23,24 In particular,
we found that, in undifferentiated myoblasts, KvDMR1 is
involved in a repressive long-range chromatin interaction with
Cdkn1c promoter, mediated by CTCF. Upon differentiation
stimuli, MyoD binds to an E-box-like sequence adjacent to a
CTCF binding site within KvDMR1, causing the disruption of
the chromatin loop and the induction of maternal Cdkn1c
expression. This finding indicates that KvDMR1, in addition to
control the imprinting, is also involved in the differentiation-
dependent regulation of Cdkn1c. Interestingly, we observed
that MyoD also induces the expression of at least another gene
of the domain, Kcnq1, again from the maternal allele. More-
over, other reports showed that Cdkn1c and Kcnq1 are co-
induced in other cell types in response to other factors, such as
p7325 and E47,26 suggesting a general role of KvDMR1, a com-
mon regulatory element for the 2 genes, in the differentiation-
dependent regulation of the entire locus.
During our studies on Cdkn1c induction, we observed
that some myogenic cell types are refractory to the induc-
tion of Cdkn1c. These cell types, that we termed unrespon-
sive in comparison with the normally responsive cells,
represented a very useful experimental tool to highlight the
existence of cis-acting constraints preventing Cdkn1c expres-
sion21,22 and to reveal the functional importance of the
MyoD binding to KvDMR1.23,24 In particular, we found
that, in unresponsive cells, MyoD is unable to interact with
KvDMR1-chromatin and promote the release of the CTCF-
mediated loop.
In the present work, we investigated the molecular mecha-
nisms that prevent KvDMR1 accessibility to MyoD-dependent
regulation. We suggest that the accumulation of H3 lysine 9
dimethylation (H3K9me2) at KvDMR1, by preventing the
binding of MyoD and the consequent reorganization of chro-
matin architecture, plays a critical role in preventing Cdkn1c
induction in muscle cells.
Results
5-AZA treatment restores the functional interaction of
MyoD with KvDMR1 and the induction of Cdkn1c
To investigate the nature of the constraints underlying the
inability to upregulate Cdkn1c, we took advantage of a myo-
genic cell system based on the muscle conversion of fibro-
blast cells by exogenously expressed MyoD. This system, in
addition to be recognized as a reliable model of both in
vitro and in vivo myogenesis,27,28 is particularly suitable for
the identification and analysis of MyoD targets. It was dur-
ing the examination of a number of different fibroblast cell
types, showing comparable abilities to undergo apparently
normal differentiation in response to MyoD, that we found
the occurrence of their differential responsiveness to the
induction of Cdkn1c.19,21,22 In the present work, we
employed immortalized mouse C57BL/6 as responsive and
C3H10T1/2 as unresponsive fibroblasts, the 2 cell types in
which we had previously examined in most detail the role
of MyoD in regulating the long-range interaction between
KvDMR1 and Cdkn1c promoter.23,24 Comparison of the
promoter21 and KvDMR1 (Supplementary Fig. 1) sequences
between the 2 cell types revealed a complete identity, thus
suggesting the existence of some epigenetic restriction in
unresponsive cells.
Cdkn1c is subject to a complex epigenetic regulation involv-
ing the cooperation of proximal, such as the promoter region,
and distal regulatory elements, such as KvDMR1. DNA methyl-
ation is the most understood epigenetic modification, in
regards to both the strategy of its propagation through cell divi-
sions and the mechanisms by which it affects transcription.29-31
CpG dinucleotides are the main target of DNA methylation, a
modification consisting in the addition of a methyl group on
the position 5 of cytosine. DNA methylation of regulatory ele-
ments is generally associated with altered gene expression32,
due to direct interference with transcription factor binding
and/or recruitment of chromatin modifying enzymes that pro-
mote chromatin compaction.33-35 Both Cdkn1c promoter and
KvDMR1 are within potentially methylatable CpG islands. In
this regard, the use of pharmacological inhibitors of DNA
methylation or genetic ablation of individual DNA methyl-
transferases suggested that the DNA methylation status of the 2
regulatory elements exert opposite effects on Cdkn1c expres-
sion. In fact, while promoter and gene body hypermethylation
have been implicated in Cdkn1c silencing during imprinting,36
prior to differentiation,21 and in tumor cells.37-40 KvDMR1
hypermethylation, present on the maternal allele, is believed to
support maternal-specific Cdkn1c expression. The latter effect
has been ascribed to the repression of Kcnq1ot1 promoter.16
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To explore whether and how DNA methylation was
involved in the molecular mechanism that prevents Cdkn1c
induction in unresponsive cells, we analyzed the effects of a
pharmacological inhibitor of DNA methylation, 5-Azacytidine
(5-AZA) on the MyoD-dependent induction of the gene. Unre-
sponsive fibroblasts were infected with a MyoD-expressing ret-
roviral vector in concomitance with 5-AZA or control
treatment. Samples were collected 24 h after the shift to differ-
entiation medium, which promotes MyoD activity, in order to
carry out different kinds of analysis in parallel. To check the
effect of 5-AZA we first performed a methylated DNA-immu-
noprecipitation (MeDIP) assay. Genomic DNA was prepared
as described in the Materials and Methods section and subject
to immunoprecipitation with an anti-5-methylcytidine anti-
body. Immunoprecipitated DNA was then analyzed by qPCR
for the enrichment of the KvDMR1 sub-region bound by
MyoD and of Cdkn1c promoter. As expected, 5-AZA treatment
decreased the DNA methylation of both regions (Fig. 1A). To
ascertain whether DNA demethylation allows the restoration of
Cdkn1c induction by MyoD, we examined its mRNA levels by
RT-qPCR. As reported in Fig. 1B, 5-AZA treatment causes an
evident rescue of Cdkn1c expression in unresponsive cells.
Importantly, the upregulation of Cdkn1c was only evident in
the presence of MyoD and not in 5-AZA-treated control cells,
supporting the hypothesis that 5-AZA was affecting the MyoD-
dependent regulation of Cdkn1c rather than causing the direct
de-repression of the gene. Unlike Cdkn1c, the expression of
myogenin, that is not associated to a CpG island,41 was not
increased; rather, it appeared slightly decreased (Fig. 1C).
Interestingly, MyoD expression did not change after treatment
with 5-AZA (Fig. 1C). This was unexpected at first sight, since
old seminal studies showed that 5-AZA treatment causes the
myogenic conversion of C3H10T1/2 fibroblasts,42,43 as a conse-
quence of endogenous MyoD de-repression.44,45 The apparent
discrepancy of our result with previous studies could be easily
explained if considering that we analyzed MyoD levels at earlier
times after 5-AZA treatment, compared to those employed for
detecting muscle-converted cell clones. Moreover, our cells
overexpress exogenous MyoD, which constant levels probably
mask minor variations caused by 5-AZA at the endogenous
gene. Whatever the explanation, this finding further reinforces
the claim that it is demethylation of Cdkn1c regulatory ele-
ments, and not an increased myogenic conversion, the major
cause of the rescue of Cdkn1c expression. In light of the known
contribution of promoter DNA methylation in the mainte-
nance of imprinting, and of the previously reported ability of
5-AZA to cause loss of imprinting in uniparental mouse
fibroblasts,46 we wondered if the observed rescue of Cdkn1c
expression following 5-AZA treatment of unresponsive cells
reflected the reactivation of the paternal allele. We could not
directly address this question in unresponsive cells due to the
unavailability of allele-specific polymorphisms. However, in
order to obtain at least indirect evidence of the parental origin
of Cdkn1c during differentiation induced by MyoD in the pres-
ence of 5-AZA, we decided to take advantage of fibroblast cells
derived from hybrid mice (C57BL/6 female X SD7 male), carry-
ing allele-specific single nucleotide polymorphisms (SNPs) in
the distal part of chromosome 7 and behaving as responsive.24
Figure 1. 5-AZA treatment restores Cdkn1c expression in unresponsive cells. (A) qPCR analysis of the MeDIP assay performed on the KvDMR1 sub-region bound by MyoD
(KvDMR1-MyoD) and on the Cdkn1c promoter in untreated (Ctr) and 5-AZA-treated samples. Values are expressed as percentages of Input DNA. Error bars indicate stan-
dard error of the mean (SEM) for each sample analyzed in triplicate. (B) RT-qPCR in unresponsive cells (C3H10T1/2 fibroblasts) infected with either the empty vector retro-
virus (Vector) or the MyoD-encoding retrovirus (MyoD) and treated as above. Statistical significance: P < 0.01 (). (C) RT-qPCR analysis of myogenin and MyoD expression
in unresponsive cells infected with MyoD and treated as above. Values, relative to those of 18S RNA, are the mean of 4 independent experiments § SEM. Statistical signif-
icance: ns (not significant). (D) Allele-specific RT-qPCR analysis of Cdkn1c expression in hybrid fibroblasts (C57BL/6 female x SD7 male) infected with MyoD and treated as
above; values, normalized on 18S expression, are the mean of 3 independent experiments § SEM. Statistical significance: ns. M: maternal; P: paternal.
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Cells were treated as described above for unresponsive cells and
Cdkn1c levels were measured by allele-specific RT-qPCR. As
reported in Fig. 1D, 5-AZA treatment not only did not increase
the total Cdkn1c expression levels, consistently with the
absence of the epigenetic restriction present in unresponsive
cells, but also did not affect at all the paternal Cdkn1c allele.
This renders unlikely the possibility that 5-AZA treatment
restores the Cdkn1c responsiveness to MyoD by inducing loss
of imprinting through promoter demethylation.
The possible effect of DNA demethylation on the functional
interaction of MyoD with KvDMR1 was determined by chroma-
tin immunoprecipitation (ChIP) assays. MyoD-bound chromatin
was immunoprecipitated from unresponsive cells, either treated
with 5-AZA or untreated, and analyzed by qPCR using primers
specific for the amplicon indicated in Fig. 2A (ChIP/MeDIP
amplicon). As shown in Fig. 2B, 5-AZA treatment restored the
physical interaction of MyoDwith KvDMR1.We have previously
shown that this interaction, only enabled in responsive cells,
accounts for the disruption of the higher-order chromatin struc-
ture that constrains Cdkn1c promoter.24 Thus, we wanted to
determine whether the rescue of MyoD binding was associated
with the rescue of its ability to change the chromatin architecture
of the locus. To this end, we performed chromosome conforma-
tion capture (3C) assays. Crosslinked chromatin was subject to
digestion and ligation, after which hybrid fragments, deriving
from the ligation of Cdkn1c promoter and KvDMR1 sequences,
were amplified as previously described.23,24 The results reported
in Fig. 2C show that 5-AZA treatment, in concomitance with
decreased DNA methylation and increased MyoD binding, also
caused a reduction of the interaction frequency between Cdkn1c
promoter and KvDMR1, denoting the release of the chromatin
loop. These findings, taken together, indicate that the 5-AZA
effects on the MyoD-dependent induction of Cdkn1c are medi-
ated by changes occurring at KvDMR1.
Responsive and unresponsive cells exhibit differential
H3K9me2 at the KvDMR1 sub-region bound by MyoD
Previous studies addressing the genome-wide distribution of
differentially methylated regions in muscle respect to other tis-
sues revealed a significant association of these regions with the
recognition sites for myogenic bHLH factors.47,48 The MyoD
Figure 2. 5-AZA treatment restores the functional interaction of MyoD with KvDMR1. (A) Schematic diagram of the KvDMR1 region (as defined by Fitzpatrick and cow-
orkers11). The narrow vertical bars represent the position of CpG dinucleotides; the horizontal bars indicate the positions of the KvDMR1 sub-region spanning the tran-
scriptional start site and the 30-portion of Kcnq1ot1 promoter (KvDMR1-ot1) and of the KvDMR1 sub-region bound by MyoD (KvDMR1-MyoD); the small black rectangle
indicate the MyoD-binding site; the lower enlargements represent the fragments sequenced after sodium bisulfite treatment (Bisulfite amplicons 1 and 2) or amplified in
ChIP and MeDIP assays (ChIP/MeDIP amplicon), as well as the position of the CpG dinucleotides included. (B) ChIP-qPCR analysis of MyoD binding in unresponsive cells
(C3H10T1/2 fibroblasts) expressing exogenous MyoD, and treated with 5-AZA or untreated (Ctr). Values obtained for the binding to KvDMR1 were normalized to those
for the binding to myogenin promoter, which is a CpG poor region, and expressed as percentages of Input chromatin. The results, derived from 3 independent experi-
ments, are reported as mean § SEM. Statistical significance: P < 0.01 (). (C) 3C-qPCR analysis of the KvDMR1-Cdkn1c promoter interaction in cells expressing MyoD and
treated as in (A). Values are reported as fold change of the interaction frequencies in the presence of 5-AZA relative to untreated controls (Ctr). The 3C analysis of a consti-
tutive and ubiquitous long-range interaction occurring at the ERCC3 locus was used as a positive control for digestion and ligation of the 3C samples. The results shown
for both interactions correspond to the means of 2 independent experiments. Error bars represent SEM.
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binding site, which we found to be relevant for Cdkn1c induc-
tion, maps to a CpG-rich sub-region within KvDMR1 (indi-
cated as KvDMR1-MyoD in Fig. 2A). In light of the
observation that 5-AZA treatment restores MyoD binding in
unresponsive cells, we asked whether the differential accessibil-
ity of MyoD to KvDMR1 in responsive vs. unresponsive cells
could involve a differential DNA methylation status.
To address this issue, we performed a bisulfite sequence
analysis. Genomic DNA from unresponsive and responsive
cells, grown in the absence of exogenous MyoD expression, was
treated with bisulfite and amplified with appropriated sets of
primers for the fragments indicated in Fig. 2A (Bisulfite ampli-
con). Cloned PCR products were then subjected to sequencing.
As reported in Fig. 3A, the percentages of methylated CpG
sites, calculated in relation to the total CpGs of the region ana-
lyzed, appear significantly lower in responsive than in unre-
sponsive cells. However, the presence of clones appearing
either completely methylated or completely un-methylated,
rather than partially methylated, suggested that the KvDMR1
sub-region bound by MyoD, like the adjacent sub-region that
contains the Kcnq1ot1 promoter, considered critical for the
imprinting of the cluster,16 can be marked by allele-specific
methylation. We could not determine the parental origin of the
sequenced clones due to the lack of parental-specific polymor-
phisms. However, in order to address this question, we took
advantage of a SNP present in the KvDMR1-MyoD region of
C57BL/6 X SD7 fibroblasts. These cells not only allowed us to
distinguish the parental alleles, but also represented an addi-
tional responsive cell line useful for verifying the results. As
reported in Fig. 3B, bisulfite sequencing of a larger region
(Bisulfite amplicon 2) of KvDMR1-MyoD revealed the same
DNA methylation pattern, with clones either completely meth-
ylated or completely un-methylated; even though in this case
the percentage of methylated clones was higher respect to the
other responsive cell line. More importantly, we found that the
completely un-methylated clones are all of paternal origin,
while the completely methylated clones are of maternal origin.
It is likely that the same is true for the bisulfite-sequenced
clones reported in Fig. 3A and that the lower levels of DNA
methylation observed in responsive cells reflected a bias toward
the selection of paternal-specific clones, due to some technical
reason.
In light of the existence of a bidirectional cross-talk
between DNA methylation and repressive histone modifica-
tions,49,50 we reasoned that the epigenetic feature directly
responsible for the differential MyoD binding could involve
some histone modification, which would have been removed
alongside DNA methylation after 5-AZA treatment. We
focused our attention on H3K9me2, a modification cata-
lyzed by G9a and G9a-like methyltransferases51, which have
been recently recognized to play important roles in myo-
blast proliferation and differentiation.52 In addition,
H3K9me2 and DNA methylation are known to be coordi-
nated by a complex and bidirectional relationship involving
the recognition of DNA methylation by the histone methyl-
ation machinery, and vice versa.53 Furthermore, treatment
with DNA demethylating agents was reported to cause
reduction of H3K9me2 (but not H3K9me3) levels at
Figure 3. Differential methylation at the KvDMR1 sub-region bound by MyoD correlates with the imprinting status rather than with the differential responsiveness. (A)
Bisulfite sequence analysis showing the methylation status of the 27 CpG dinucleotides included in the Bisulfite amplicon 1 shown in Fig. 2 A, in unresponsive (C3H10T1/
2 fibroblasts) and responsive cells (C57BL/6 fibroblasts). Each circle indicates an individual CpG dinucleotide. Each row of circles corresponds to an individual clone of the
bisulfite-PCR product. Empty and filled circles indicate unmethylated and methylated CpGs, respectively. Absent circles represent ambiguous data. (B) Allele-specific bisul-
fite sequence analysis in hybrid fibroblasts (C57BL/6 female x SD7 male) showing the methylation status of the 38 CpGs located in the Bisulfite amplicon 2 shown in
Fig. 2A. The SNP in this region causes the loss of a CpG on the paternal (P) respect to the maternal (M) allele. The gap is represented by a dash.
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different regulatory regions.54,55 These considerations
prompted us to determine H3K9me2 levels at the
KvDMR1-MyoD binding region in unresponsive compared
to responsive cells and their possible reduction following 5-
AZA treatment. As reported in Fig. 4A the global levels of
H3K9me2 are equivalent in the 2 cell types, as determined
by Western blot analysis using an antibody specific for
H3K9me2. In contrast, as shown in Fig. 4B, the enrichment
of the modification at the KvDMR1-MyoD binding region
was significantly higher in unresponsive vs. responsive cells,
as determined by ChIP assays performed with the primers
for the ChIP/MeDIP amplicon indicated in Fig. 2A. Unlike
KvDMR1, the Cdkn1c promoter region did not appear sig-
nificantly different in the 2 cell types, just as previously
observed for DNA methylation;21 rather, it showed slightly
higher levels in responsive vs. unresponsive cells. This find-
ing further highlights the role of KvDMR1, rather than the
promoter, as the genomic region directing the epigenetic
constraint that prevents Cdkn1c induction. Interestingly, a
differential accumulation of H3K9me2 was also present on
the adjacent KvDMR1 sub-region containing the Kcnq1ot1
promoter. However, the comparison of Kcnq1ot1 levels in
responsive and unresponsive cells did not reveal any differ-
ence (Supplementary Fig. 2), thus excluding that the Cdkn1c
unresponsiveness to MyoD involves the overexpression of
the long noncoding RNA. Next, we determined whether the
5-AZA effects on the rescue of Cdkn1c expression were
associated to a reduction of H3K9me2, in concomitance
with DNA methylation levels, at the KvDMR1-MyoD
region. Unresponsive cells, treated with 5-AZA as above,
were collected for either genomic DNA or chromatin prepa-
ration. Bisulfite sequencing was performed both to confirm
the MeDIP results and to determine the methylation status
of the region at the single CpG level. As reported in
Fig. 5A, 5-AZA treatment caused a moderate but significant
reduction of DNA methylation at the KvDMR1-MyoD
region. Of course, DNA demethylation appeared to concern
the completely hypermethylated clones that presumably rep-
resent, as suggested above, the maternal allele driving
Cdkn1c expression. As expected, and according to the
MeDIP assay, Cdkn1c promoter, which is equally hyperme-
thylated in responsive and unresponsive cells,21 also under-
went moderate DNA demethylation throughout the region
(Fig. 5B).
In parallel, 5-AZA-treated and control cells were analyzed
by ChIP for H3K9me2. As reported in Fig. 5C, and according
to the previously reported influence of DNA methylation on
this modification, we found that 5-AZA treatment caused a sig-
nificant reduction of H3K9me2 at several regulatory regions
and, most remarkably, at the same KvDMR1 region where it
promotes the restoration of MyoD binding. These findings,
taken together, support the conclusion that the epigenetic con-
straint that prevents Cdkn1c induction in unresponsive cells is
related to the presence of increased levels of H3K9me2 at
KvDMR1 and that DNA demethylation, by interfering with the
maintenance of H3K9 methylation, leads to the removal of this
constraint.
Differential H3K9me2 enrichment marks KvDMR1 in
cancer cells differentially expressing Cdkn1c
Mouse and human KvDMR1 show a similar genomic orga-
nization, including the presence of E-box elements adjacent
to CTCF binding sites.23 Cdkn1c silencing has been
observed in several cancer cell types and has been found to
contribute to their malignant phenotype.1 A number of
studies, addressing the molecular mechanisms underlying
Cdkn1c repression, focused on the gain of repressive epige-
netic modifications at the promoter or on the loss of
KvDMR1 function resulting in maternal expression of
Kcnq1ot1 and biallelic silencing of Cdkn1c. In contrast, the
possible role of the accumulation of repressive modifications
at KvDMR1 in the cancer cell context has never been
considered.
We started to explore this issue by analyzing the
H3K9me2 status of KvDMR1 in 2 human breast cancer cell
lines, MCF-7 and MDA-MB-231, expressing very low and
high Cdkn1c levels, respectively.56 ChIP assays were per-
formed on the 2 cell types using the anti-H3K9me2 anti-
body and a set of primers encompassing a human KvDMR1
Figure 4. Responsive and unresponsive cells display differential H3K9me2 at KvDMR1. (A) Western blot assay showing the total level of H3K9me2 in unresponsive
(C3H10T1/2 fibroblasts) and responsive cells (C57BL/6 fibroblasts). Histone H3 was used as a loading control. (B) ChIP-qPCR analysis of H3K9me2 enrichment at the 2
KvDMR1 sub-regions and Cdkn1c promoter (Cdkn1c prom) in unresponsive and responsive cells. Actin promoter (Actin prom) was used as negative control. Values
obtained for the enrichment were normalized to those on b-globin promoter, used as an invariant control, and expressed as percentages of Input chromatin. The results,
derived from 2 independent experiments, are reported as mean § SEM. Statistical significance: P < 0.05 (). ns: not significant.
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sub-region containing a putative bHLH binding site. As
reported in Fig. 6A, a small but significant enrichment of
H3K9me2 is present in MCF-7 compared to MDA-MB-231
cells, reminiscent of the difference observed between unre-
sponsive and responsive fibroblast cells. Interestingly, as
reported in Fig. 6B, the similarity also extends to the 5-
AZA-response in MCF-7 cells, in which Cdkn1c is upregu-
lated upon treatment.
These results support the hypothesis that similar mecha-
nisms, involving repressive chromatin modifications at
KvDMR1, may participate both in Cdkn1c control during mus-
cle differentiation and Cdkn1c silencing in cancer cells.
Discussion
Using a model system previously characterized in our lab, a
pair of responsive and unresponsive cell types, we obtained evi-
dence that the presence of repressive chromatin modifications
at the KvDMR1 sub-region bound by MyoD represents a criti-
cal determinant of the response of Cdkn1c to MyoD-dependent
Figure 5. 5-AZA treatment reduces both DNA methylation and H3K9me2 at KvDMR1 in unresponsive cells. (A) The left panel shows the bisulfite sequence analysis of the
same KvDMR1-MyoD sub-region analyzed in Fig. 3 A, performed in unresponsive cells (C3H10T1/2 fibroblasts) treated with 5-AZA. The results are reported as explained
in Fig. 3A. The right panel shows quantitative analysis of the DNA methylation percentages at the entire sub-region (KvDMR1-MyoD) in 5-AZA-treated cells respect to the
control (Ctr). Values refer to the data shown in Fig. 3A, for Ctr, and in Fig. 5A for 5-AZA samples. Error bars represent SEM. Statistical significance: P < 0.001 (). (B) The
left panel shows the bisulfite sequence analysis of the Cdkn1c promoter, performed in unresponsive cells (C3H10T1/2 fibroblasts) treated with 5-AZA. The results are
reported as explained in Fig. 3A. The right panel shows the quantitative analysis of DNA methylation percentages in 5-AZA-reated respect to control sample; Values refer
to our previously reported data21 for control and to those shown in Fig. 5A for 5-AZA samples. Error bars represent SEM. Statistical significance: P < 0.001 (). (C) ChIP-
qPCR analysis of H3K9me2 enrichment at the 2 KvDMR1 sub-regions and Cdkn1c promoter (Cdkn1c prom) in untreated (Ctr) and 5-AZA treated unresponsive cells. b-glo-
bin promoter (b-globin prom) and actin promoter (Actin prom) were used as positive and negative controls respectively. Values obtained for the enrichment are the
mean of 2 independent experiments and are expressed as percentages of Input chromatin. Error bars represent SEM. Statistical significance: P < 0.05 (); ns: not
significant.
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induction. In light of the observation that 5-AZA treatment of
unresponsive cells restores the chromatin pathway involving
the binding of MyoD to KvDMR1, the disruption of the repres-
sive long-range interaction of KvDMR1 with Cdkn1c promoter
and the upregulation of the gene, we first studied the methyla-
tion status of KvDMR1. Interestingly, however, we found that
the key epigenetic feature underlying the differential respon-
siveness of the 2 cell types to the MyoD-dependent induction
of Cdkn1c is the differential enrichment of H3K9me2, rather
than DNA methylation, at KvDMR1 (see model depicted in
Fig. 7)
The function of the dimethyl mark on H3K9 has been less
investigated respect to the trimethyl mark on the same position.
However, H3K9me2 appears generally associated with faculta-
tive heterochromatin while H3K9me3 is commonly associated
with constitutive heterochromatin.57 Moreover, genome-wide
analysis of H3K9me2 distribution revealed that this modifica-
tion is present at repressed genes during development and dif-
ferentiation and seems important for gene silencing during
lineage restriction.58 The roles of H3K9me2 and G9a, the main
enzyme catalyzing this modification, are currently extensively
investigated in the muscle differentiation system. In this regard,
it has been reported that, in undifferentiated myoblasts,
H3K9me2 represses the promoters of some MyoD target genes,
such as the muscle-specific gene myogenin59 and the cell cycle
exit genes Cdkn1a (coding for the cdk inhibitor p21cip1) and
Rb1.52 In the case of myogenin promoter, the molecular mecha-
nism of repression would involve the interference with the
activity of chromatin-bound MyoD through the cooperation
with other histone modifications.60 It has also been reported
that G9a, in addition to methylate histone H3, also methylates
the MyoD protein,61 indicating that the relationship between
G9a, H3K9me2, and MyoD functions is very complex. On the
other hand, we found that the presence of high levels of
H3K9me2 at KvDMR1 correlates with the failure of MyoD to
access chromatin, thus suggesting an additional way by which
this histone modification affects MyoD-dependent tran-
scription.
H3K9me2 chromatin targeting can be mediated by several
mechanisms involving sequence-specific transcription factors
interacting with histone methyltransferases, DNA methylation,
other chromatin-binding complexes, and noncoding RNAs,57
Figure 6. Cdkn1c silencing in human cancer cells correlates with H3K9me2 enrichment at KvDMR1. (A) ChIP-qPCR analysis of H3K9me2 enrichment at KvDMR1 in MCF-7
and MDA-MB-231 (MDA). Values obtained for the enrichment were normalized to those of APOC-III promoter, used as a positive control, and expressed as percentages of
Input chromatin. The results, derived from 2 independent experiments, are reported as mean § SEM. Statistical significance: P < 0.05 (). (B) RT-qPCR analysis of Cdkn1c
expression in MCF-7 cells untreated (Ctr) or 5-AZA treated samples. Values, relative to those of GAPDH RNA, are the mean of 3 independent experiments§ SEM. Statistical
significance: P < 0.05 ().
Figure 7. Schematic model of the mechanism by which 5-AZA restores the functional interaction of MyoD with KvDMR1 and the rescue of Cdkn1c induction in unrespon-
sive cells. In unresponsive cells MyoD cannot bind to KvDMR1, due to the presence of a repressive chromatin conformation involving H3K9me2. The failed MyoD binding
does not allow the disruption of the repressive chromatin contact between KvDMR1 and Cdkn1c promoter and Cdkn1c is not induced. After 5-AZA treatment not only
DNA methylation but also H3K9me2 levels decrease at KvDMR1, allowing MyoD binding to KvDMR1 and causing the release of the chromatin loop and thus induction of
Cdkn1c.
8 O. ANDRESINI ET AL.
suggesting that additional epigenetic features underpin the
modification we have highlighted in the present work. It is
worth mentioning that Kcnq1ot1 has been found to interact
with G9a and other histone methyltransferases as well as with
DNA methyltransferase 1.17 As mentioned above, Kcnq1ot1 is
expressed at comparable levels in unresponsive vs. responsive
cells. Although this finding would indicate that Kcnq1ot1 does
not play a primary role in determining the responsiveness to
MyoD-dependent induction of Cdkn1c, we cannot exclude that
the long noncoding RNA could differentially interact with the
Cdkn1c locus in the 2 cell types.
The differential enrichment of H3K9me2 at KvDMR1 in
responsive and unresponsive cells does not correspond to a
pre-existing differential DNA methylation. In fact, the allele-
specific analysis of bisulfite-sequenced clones from a cell line
polymorphic for maternal and paternal KvDMR1 revealed that
their DNA methylation status reflected their parental origin.
The reduction of H3K9me2 levels in response to DNA deme-
thylating agents has been already observed in previous studies
concerning the epigenetic reactivation of tumor suppressor
genes.62,63 This effect was ascribed both the removal of a plat-
form for the recruitment of histone methyltransferases
(through methylated CpG binding proteins) and to a more
indirect mechanism involving a DNA demethylation-indepen-
dent decrease of G9a, the main enzyme promoting H3K9me2
deposition. Our finding that 5-AZA treatment concomitantly
reduces both H3K9me2 and DNA methylation levels suggests
that DNA demethylation is directly involved in the observed
histone demethylation.
We recognize that the 5-AZA-induced rescue of Cdkn1c
expression could involve modifications not only at KvDMR1,
but also at the promoter region. However, we did not observe
Cdkn1c expression after treatment with 5-AZA in the absence
of MyoD, despite promoter demethylation. This suggests that
the main determinant of the restored Cdkn1c expression is the
restored MyoD binding to KvDMR1. It is worth to underline
that the epigenetic changes compatible with MyoD binding do
not influence the imprinting status of Cdkn1c, which is exclu-
sively expressed from the maternal allele. This supports the
conclusion that the KvDMR1 sub-region bound by MyoD also
plays regulatory roles other than the imprinting control.
Remarkably, we found differential enrichment of H3K9me2
at KvDMR1 also in 2 human breast cancer cell lines, MCF-7
and MDA-MB-231, differentially expressing Cdkn1c. More-
over, MCF-7 cells, in which Cdkn1c is repressed, show upregu-
lation of the gene following 5-AZA treatment. These
observations not only support the results obtained in the mus-
cle differentiation system, but also extend the importance of
the proposed model. In light of previous findings showing that
other bHLH proteins, such as Mash2, E47, and ID2, regulate
Cdkn1c transcription in neural cells,26,64 we hypothesize that a
shared regulatory mechanism, involving a long-range interac-
tion of KvDMR1 with Cdkn1c promoter and its reorganization
upon binding of bHLH factors, may participate in Cdkn1c
repression and de-repression in more than one cell type.
In summary, this work highlights a still uncharacterized
mechanism of Cdkn1c silencing, pointing to the epigenetic sta-
tus of KvDMR1 as a critical feature determining the availability
of this CKI for induction by regulatory factors. Importantly,
the KvDMR1 sub-region involved in the differentiation-depen-
dent regulation of Cdkn1c appears functionally distinct from
that involved in the imprinting control. These results could
have an interesting follow up in the fields of cancer and BWS
research. It will be compelling to investigate if H3K9me2
enrichment at the regulatory element identified in this work is
also present in BWS patients and in other cancer types where
Cdkn1c is not expressed. If this were the case, the epigenetic sta-
tus of this region could be used as a prognostic or diagnostic
marker.
A more detailed knowledge of the complex roles of DNA
and histone methylation at KvDMR1 not only will clarify the
molecular mechanisms underlying the restriction of Cdkn1c
expression during development and its silencing in some
pathologies, but also will provide a more integrated picture of
the effects of using epigenetic drugs in attempts to restore
Cdkn1c expression.
Materials and methods
Cell cultures
Mouse C3H10T1/2 (unresponsive), C57BL/6 (responsive),
C57BL/6 x SD7 (responsive) fibroblasts, MCF-7, and MDA-
MB-231 breast cancer cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM) (Gibco) supplemented with 10% fetal
bovine serum (FBS) (Gibco). Production of MyoD-expressing
retrovirus and retroviral infections were performed as previ-
ously described.21 MyoD activity was stimulated by shifting cell
cultures to low serum-containing differentiation medium
(DMEM supplemented with 0.5% FBS). Five-AZA treatment of
unresponsive fibroblasts and MCF-7 cells was performed by
adding 4 mM 5-AZA (Sigma-Aldrich) to the culture medium.
The 5-AZA-containing medium was changed every day for 4 d.
MeDIP assay
Genomic DNA was extracted and purified by standard proce-
dures. DNA was sonicated to obtain fragments of an average
length of 300–600 bp. Sonicated DNA (6 mg) was resuspended
in 500 mL of Immunoprecipitation Buffer (Ip Buffer; 10 mM
sodium phosphate pH D 7, 140 mM NaCl, 0.05% Triton X-
100). DNA was denatured at 95C and then incubated with
5 mg of 5-Methylcytidine antibody (Bi-Mecy 0100, Eurogentec)
or without antibody (No Ab sample) overnight at 4C. Protein
G magnetic beads (40 mL) were added to each sample and incu-
bated 4 h at 4C. Before washing, the supernatant of the no anti-
body control was taken as Input sample. After 3 washes with Ip
Buffer, samples were treated with proteinase K and incubated
2 h at 56C and overnight at 37C. DNA was extracted with
phenol-chloroform, precipitated with ethanol, and re-suspended
in 50 ml of distilled water. Quantitative PCR (qPCR) analyses of
immunoprecipitated KvDMR1 and Cdkn1c promoter regions
were performed each in triplicate using 5 ng of DNA, GoTaq
qPCR Master Mix (Promega) and the primer pairs: KvDMR1,
50-GCACAAGTCGCAAGTCCGCG-30 and 50-ATGGAGCC-
CAGCCGCGAAAG-30, specific for the KvDMR1-MyoD
sub-region indicated in Fig. 2A; Cdkn1c prom, 50ACT
GAGAGC-AAGCGAACAGG and 50ACCTGGCTGATTGGT
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GATGG. The reactions were performed in the “CFX Connect
Real Time system” termocycler (Bio-Rad).
Bisulfite modification and sequencing
Sodium bisulfite treatment was carried out as previously
described21 with some modifications. DNA (5 mg), previously
digested with BamHI, was denatured with 0.3 M NaOH at
42C for 20 min. Bisulfite reactions were performed in 5.8 M
urea, 3.7 M sodium bisulfite and 6.67 mM hydroquinone at
55C for 4 h. The DNA was desalted using Wizard Clean-Up
system (Promega). The reactions were terminated by further
incubation in 0.3M NaOH at 37C for 20 min. Samples were
co-precipitated with 5 mg of molecular biology grade glycogen
in sodium acetate/ethanol at ¡20C for 16 h. Pellets were then
resuspended in 50 ml of distilled water. Modified DNA was
used as a template in PCR reactions using the following pri-
mers: For bisulfite amplicon 1: F, 50-TTGGAGAGTTTT-
TTTGTTTAGTTTG and R, 50CAAAACCACCC-CTACTTC-
TATAAAC, which amplify the fragment indicated in Fig. 2A.
Amplification consisted of one cycle at 95C for 5 min followed
by 35 cycles at 95C for 30 sec, 56C for 60 sec and
72C for 60 sec. For Bisulfite amplicon 2: F, 50-GATTTT-
TATGGTGAGG-TTTTA-30 and R, 50-CAAAACCACCCC-
TACTTCTAT-30 that amplify the fragment indicated in
Fig. 2A. Amplification consisted of one cycle at 95C for 5 min
followed by 35 cycles at 95C for 30 sec, 57C for 60 sec and
72C for 60 sec. For Cdkn1c promoter: F, 50-TGTTGAAATT-
GAAAATATTATATTATGTTA-30 and R, 50- TAAATAAAA-
CCCCTTACACAAC-CC-30. Amplification consisted of one
cycle at 95C for 5 min followed by 35 cycles at 95C for 30 sec,
54C for 60 sec and 72C for 60 sec.
PCR products were cloned into pGEM-T Easy vector using
TA cloning kit (Promega) and transformed into E. cloni 5-a
chemically competent E. coli cells (Lucigen). A number of posi-
tive clones were randomly selected for automated sequencing.
ChIP assays
MyoDChIP assays were carried out as described.21 Chromatin was
immunoprecipitated with anti-MyoD antibody (sc-760; Santa
Cruz Biotechnology, Inc.) or with normal rabbit IgG (12–370;
Merk Millipore). qPCR analysis was performed in triplicate for
each of 3 independent experiments, using 5 ng of DNA, Go Taq
qPCR Master Mix (Promega), and the following primer pairs: F,
50-GCACAAGTCGCAAGTCCGCG-30 and R, 50-ATGGAGCC-
CAGCCGCGAAAG-30 specific for the KvDMR1-MyoD sub-
region indicated in Fig. 2A; 50-TGGCAGGAACAAGCC-TT-
TTGCGA-30 and 50-AGTCCGCTCATAGCCCG-GGG-30 for
myogenin promoter.
Histone-ChIP assays were performed using 50mg of chromatin
for sample and 5 mg of specific antibody anti dimethyL-histone
H3K9 (Millipore, 05–1249) or with normal mouse IgG Antibody
(Millipore, 12–371) . Each sample was diluted 10-fold with dilution
buffer (5 mM EDTA, 50 mM Tris-HCl pH8.0, 0.5%NP40,
200 mMNaCl, and protease and phosphatase inhibitors). Samples
were incubated overnight with gently rotation at 4C. Before wash-
ing, the supernatant of the IgG sample was taken as Input. Each
sample was washed twice with Low Salt buffer (0.1% SDS, Triton-
X-100, 2 mM EDTA, 20 mM Tris-HCl pH D 8.1, 150 mM NaCl)
and with High Salt buffer (0.1% SDS, Triton-X-100, 2 mM EDTA,
20 mM Tris-HCl pH D 8.1, 500 mM NaCl); one time with LiC
Buffer (0.25 M LiCl, 1% NP40, 1% deoxycholate, 1 mM EDTA,
10 mM Tris-HCl pH D 8,1) and TE Buffer (10 mM Tris-HCl,
1 mMEDTA pHD 8).
Samples were eluted with Elution Buffer (1x TE, 0.5% SDS),
treated with RNAse A for 10 min at room temperature and
with Proteinase K for 5 h at 62C. DNA was extracted with
phenol-chloroform, precipitated with ethanol, and re-sus-
pended in 50 ml of distilled water. After immunoprecipitation,
the DNA quantity of each sample was measured. The different
regions were amplified using the same DNA amount with the
following primers: F, 50-GCACAAGTCGCAAGTCCGCG-30
and R, 50-ATGGAGCCCAGCCGCGAAAG-30, specific for the
KvDMR1-MyoD sub-region and F, 50-GGCTGCCACGTCAC-
CAA-30 and R, 50-CCTGACTGGACCAAAATGCA-30, for
KvDMR1-ot1 sub-region; F, 50GAAGCCTGATTCCGTAGA-
GC-30 and R, 50-CAACTGATCCTACCTCACCTTATATGC-
30 for b-globin promoter; F, 50-GTGACATCCACACCCAGA-
GG-30 and R, 50GAATAGCCTCCGCCCTTG-30, for Actin pro-
moter:; F, 50-GGAGGAGGGGTCATTCTCTC-30 and R, 50-
GACAGGGGTCACATCCATTC-30 for Cdkn1c promoter; F,
50-CCGTTCTGCCTGGAGACTG-30 and R, 50-AATGACAG-
GACACGGCACAT-30, for hKvDMR1 E-box; F, 50-CGGGA-
CAGCAGCCTGGATT-30 and R, 50-GCTCCTCTTGCCCCT-
CTTCAT-30, for human APOC-III promoter.
Histone extraction and Western blot
Cells were harvested and washed twice with ice-cold PBS, then
resuspended with Buffer A (20 mM Hepes pH D 7.9, 1 M KCl,
0.2MEDTA pHD 7, 0.1MEGTApHD 8, 1mMDTT and prote-
ase and phosphatase inhibitors). Cells were incubated in ice for
15 min, 0.6% NP40 was added and the solution was gently stirred.
After centrifugation, the pellet was washedwith Buffer A and resus-
pended with cold 0.4 M HCl. The extracted nuclei were incubated
in ice for 1 h and then centrifuged. The supernatant was precipi-
tated overnight with 5 volumes of cold acetone. After centrifuga-
tion, the pellet was washed with acetone, air dried, and
resuspended with water. Proteins (15 mg) were loaded on a 15%
polyacrylamide gel and transferred to nitrocellulose membranes by
electroblotting. Membranes were blocked with 5% non-fat dry
milk in PBS containing Tween 20 at room temperature and incu-
bated with the primary antibody overnight at 4Cwith anti-histone
H3 (Millipore, 07–690) diluted 1:1000 and anti-dimethyL-histone
H3K9 (Millipore, 05–1249) diluted 1:4000. After washing 3 times
with TBST solution, membranes were incubated in a 1:10000 or
1:20000 dilution of peroxidase-conjugated anti-mouse or anti-rab-
bit antibodies for 1 h (Bio-Rad) at room temperature. Proteins
were detected using the ECL chemiluminescence system
(Cyanagen).
3C assays
Crosslinking, nuclei isolation, and DNA digestion and ligation
were performed as previously described.23,24 qPCR was per-
formed in triplicate for each of 2 independent experiments
with the following primers: 50-CCTTCGACCATGGTGAGG-
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TC-30, 50GTGCTGAAACGATCCACACG-30 for KvDMR1-
Cdkn1c; 50-ATGGCCTGAAGAAACCGC-30, 50-CTTAGGCA-
ACACACTCAAGC-30 for ERCC3 locus.
Gene expression analysis
Total cellular RNA was extracted using the High Pure RNA
Isolation Kit according to the manufacturer’s instructions
(Roche Diagnostics) and 500 ng of total RNA was reverse tran-
scribed with the iScript cDNA Synthesis Kit (Bio-Rad). Diluted
cDNAs were subjected to qPCR with the following primer sets:
50-AACTTCCAGCAGGATGTGCC-30 and 50-CATCCACTG-
CAGACGACCAG-30 for Cdkn1c; 50-GTCTCTTCCTGAAGC-
CAGTTGCG-30 and 50-TGCAAATGCTTGGCCCCCAGAG-
30 for myogenin; 50-CCCGGCGGCAGAATGGCTAC-30 and
50-CTGCCAAAAGCAGCGCAGGC-30 for MyoD; 50-ACGA-
CCCATTCGAACGTCTG-30 and 50-GCACGGCGACTACCA-
TCG-30 for 18S (used as a housekeeping gene); F, 50-TTCTG-
GAGGCGATTGAGGC-30 and R, 50-AGCAACCAGAACCA-
GGTGAGAG-30 for Kcnq1ot1; F, 50-CAGATCTGACCTCA-
GACCCA-30 and R, 50-CCTGTTCCTCGCCGTCCC-30 for the
maternal allele of Cdkn1c; F, 50-CAGATCTGACCTCAGA-
CCCG-30 and R, 50-GACCTGTTCCTCGCCATCCT-30 for the
paternal allele of Cdkn1c; F, 50-GGACGAGACAGGCGAA-
CCC-30 and R, 50-TCTGCGTGTGCGAGGGAC-30 for human
Cdkn1c; F, 50-GACAGTCAGCCGCATCTTCT-30 and R, 50-
GCGCCCAATACGACCAAATC30 for human GAPDH.
Statistical analysis
For statistical analysis, comparisons were performed using
parametric Student’s t-test analysis or non-parametric Mann-
Whitney U-tests, depending on the normality of the distribution,
as assessed using the Kolmogorov-Smirnov statistics. Statistical sig-
nificance is shown as P< 0.05 or  P< 0.01 or P< 0.001 ()
For the quantitative analysis of bisulfite treated samples the
percentage of methylation of each CpG was calculated and
paired t-test was performed to compare control and 5-AZA
samples.
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